Literature DB >> 30783501

Advance of Seriniquinone Analogues as Melanoma Agents.

Justin C Hammons1, Lynnie Trzoss1, Paula C Jimenez2, Amanda S Hirata3, Leticia V Costa-Lotufo3, James J La Clair4, William Fenical1.   

Abstract

Seriniquinone, a marine natural product, displayed potent cytotoxicity and selectivity against melanoma cancer cells. This selectivity, combined with a novel mode of action (MOA), prompted studies to translate a pharmacologically relevant lead. Herein, we report on structure-activity relationships (SARs), and provide a strategy to prepare analogues that retain activity and offer an improved water solubility and isomeric purity. From intermediates made on a gram-scale, derivatives were prepared and evaluated for their antiproliferation activity and melanoma selectivity. Overall these studies provide methods to install side chain motifs that demonstrate a common, and yet unique, biological profile.

Entities:  

Year:  2019        PMID: 30783501      PMCID: PMC6378664          DOI: 10.1021/acsmedchemlett.8b00391

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  4 in total

Review 1.  Preclinical Development of Seriniquinones as Selective Dermcidin Modulators for the Treatment of Melanoma.

Authors:  Amanda S Hirata; James J La Clair; Paula C Jimenez; Leticia Veras Costa-Lotufo; William Fenical
Journal:  Mar Drugs       Date:  2022-04-28       Impact factor: 6.085

Review 2.  Biologically active marine natural products and their molecular targets discovered using a chemical genetics approach.

Authors:  David E Williams; Raymond J Andersen
Journal:  Nat Prod Rep       Date:  2019-11-21       Impact factor: 13.423

3.  Verrucosamide, a Cytotoxic 1,4-Thiazepane-Containing Thiodepsipeptide from a Marine-Derived Actinomycete.

Authors:  Vimal Nair; Min Cheol Kim; James A Golen; Arnold L Rheingold; Gabriel A Castro; Paul R Jensen; William Fenical
Journal:  Mar Drugs       Date:  2020-11-05       Impact factor: 5.118

4.  Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas.

Authors:  Amanda S Hirata; Paula Rezende-Teixeira; João Agostinho Machado-Neto; Paula C Jimenez; James J La Clair; William Fenical; Leticia V Costa-Lotufo
Journal:  Molecules       Date:  2021-12-04       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.